
November 7, 2017 - By Hazel Jackson
Among 15 analysts covering GlaxoSmithKline (NYSE:GSK), 6 have Buy rating, 1 Sell and 8 Hold. Therefore 40% are positive. GlaxoSmithKline had 23 analyst reports since September 8, 2015 according to SRatingsIntel. Berenberg upgraded the shares of GSK in report on Friday, May 26 to “Buy” rating. The company was upgraded on Wednesday, January 27 by Bryan Garnier & Cie. Jefferies upgraded the stock to “Buy” rating in Thursday, July 14 report. The rating was initiated by Cantor Fitzgerald with “Hold” on Friday, February 26. The firm has “Neutral” rating given on Tuesday, October 20 by Credit Suisse. Morgan Stanley downgraded GlaxoSmithKline plc (ADR) (NYSE:GSK) on Friday, September 8 to “Underweight” rating. The firm has “Buy” rating by Investec given on Thursday, October 20. Bank of America upgraded the shares of GSK in report on Wednesday, December 9 to “Buy” rating. The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) earned “Neutral” rating by JP Morgan on Wednesday, April 26. Piperjaffray initiated the shares of GSK in report on Friday, September 23 with “Overweight” rating. Below is a list of GlaxoSmithKline plc (ADR) (NYSE:GSK) latest ratings and price target changes.26/10/2017 Broker: Bank of America Rating: Hold Downgrade08/09/2017 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Underweight Downgrade05/07/2017 Broker: Citigroup Old Rating: Buy New Rating: Neutral Downgrade16/06/2017 Broker: J P Morgan Chase Co Rating: Neutral Maintain26/05/2017 Broker: Berenberg Old Rating: Hold New Rating: Buy Upgrade About 2.31M shares traded. GlaxoSmithKline plc (ADR) (NYSE:GSK) has risen 4.26% since November 7, 2016 and is uptrending. It has underperformed by 12.44% the S&P500.GlaxoSmithKline plc is a global healthcare company. The company has market cap of $86.69 billion. The Firm operates through three divisions: Pharmaceuticals, Vaccines and Consumer Healthcare. It has a 28.62 P/E ratio. The Firm focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus /infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



(adsbygoogle = window.adsbygoogle || []).push({});
TRADE IDEAS REVIEW – IS THIS THE BEST STOCK SCANNER?

Trade Ideas is arguably one of the top scanning tools available on the market right

Trade Ideas Pro helps traders find the best setups in the market right NOW

Scottrade and E*TRADE license Trade Ideas proprietary technology for their premium trading platforms. We have fully automated trading available through Lightspeed and Interactive Brokers.Trade Ideas is the BEST Tool for Scanning. I would be LOST without Trade ideas. Ross Cameron – Warrior Trading